Profile data is unavailable for this security.
About the company
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.
- Revenue in USD (TTM)81.63m
- Net income in USD-20.23m
- Incorporated2015
- Employees76.00
- LocationFulcrum Therapeutics Inc26 Landsdowne StreetCAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 651-8851
- Fax+1 (302) 655-5049
- Websitehttps://www.fulcrumtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Generation Bio Co | 13.17m | -158.43m | 185.54m | 174.00 | -- | 1.61 | -- | 14.08 | -2.39 | -2.39 | 0.1989 | 1.73 | 0.0393 | -- | 77.49 | 75,712.64 | -47.28 | -36.96 | -51.64 | -39.21 | -- | -- | -1,202.56 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
Caribou Biosciences Inc | 33.11m | -123.44m | 187.05m | 158.00 | -- | 0.6025 | -- | 5.65 | -1.39 | -1.39 | 0.3763 | 3.44 | 0.0917 | -- | 15.61 | 209,576.00 | -34.17 | -- | -37.56 | -- | -- | -- | -372.78 | -- | -- | -1,231.11 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
Vaxart Inc | 13.93m | -75.66m | 189.78m | 109.00 | -- | 2.37 | -- | 13.63 | -0.4707 | -0.4707 | 0.0861 | 0.3518 | 0.1178 | -- | 5.80 | 127,779.80 | -64.01 | -49.60 | -73.18 | -54.86 | -- | -- | -543.21 | -1,398.00 | -- | -226.73 | 0.0507 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
CytoDyn Inc | 0.00 | -51.32m | 194.26m | 9.00 | -- | -- | -- | -- | -0.0527 | -0.0527 | 0.00 | -0.1103 | 0.00 | -- | -- | 0.00 | -444.45 | -259.15 | -- | -- | -- | -- | -- | -232,918.20 | -- | -2.76 | -- | -- | -- | -- | 35.70 | -- | -- | -- |
Sangamo Therapeutics Inc | 12.28m | -249.68m | 199.93m | 405.00 | -- | 8.44 | -- | 16.29 | -1.38 | -1.38 | 0.0664 | 0.1138 | 0.0587 | -- | 7.45 | 30,313.58 | -119.44 | -26.09 | -153.51 | -31.04 | -- | -- | -2,033.68 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
MacroGenics Inc | 41.02m | -136.37m | 205.73m | 339.00 | -- | 3.56 | -- | 5.02 | -2.19 | -2.19 | 0.6583 | 0.9218 | 0.1619 | 6.62 | 6.51 | 120,997.00 | -53.82 | -37.76 | -67.56 | -45.53 | 79.37 | -- | -332.47 | -133.96 | 2.69 | -172.62 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
XBiotech Inc | 0.00 | -35.01m | 206.84m | 94.00 | -- | 1.05 | -- | -- | -1.15 | -1.15 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -15.53 | 31.88 | -16.32 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0484 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
Fulcrum Therapeutics Inc | 81.63m | -20.23m | 209.67m | 76.00 | -- | 0.764 | -- | 2.57 | -0.3507 | -0.3507 | 1.31 | 4.40 | 0.2746 | -- | 29.13 | 1,074,079.00 | -6.81 | -50.55 | -7.14 | -55.91 | -- | -- | -24.79 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
Pyxis Oncology Inc | 16.15m | -59.20m | 217.50m | 51.00 | -- | 1.28 | -- | 13.47 | -1.26 | -1.26 | 0.3269 | 2.88 | 0.0842 | -- | -- | 322,920.00 | -30.87 | -- | -33.12 | -- | 97.06 | -- | -366.67 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
Codexis Inc | 60.89m | -76.36m | 219.87m | 174.00 | -- | 3.58 | -- | 3.61 | -1.09 | -1.09 | 0.8723 | 0.8665 | 0.3595 | 6.27 | 3.58 | 349,942.50 | -45.08 | -17.13 | -56.05 | -20.23 | 77.95 | 77.29 | -125.41 | -37.04 | 2.92 | -- | 0.3158 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
Omeros Corp | 0.00 | -199.92m | 227.15m | 198.00 | -- | -- | -- | -- | -3.32 | -2.35 | 0.00 | -2.15 | 0.00 | -- | -- | 0.00 | -45.24 | -55.51 | -58.74 | -70.10 | -- | -- | -- | -- | -- | -5.74 | 1.42 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Compass Therapeutics Inc. | 850.00k | -47.24m | 228.40m | 32.00 | -- | 1.56 | -- | 268.70 | -0.3573 | -0.3573 | 0.0064 | 1.06 | 0.0051 | -- | -- | 26,562.50 | -28.22 | -41.75 | -29.94 | -46.41 | -- | -- | -5,557.88 | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
Cabaletta Bio Inc | 0.00 | -89.98m | 229.59m | 136.00 | -- | 1.14 | -- | -- | -1.92 | -1.92 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -44.76 | -33.76 | -47.90 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
Acrivon Therapeutics Inc | 0.00 | -69.00m | 231.36m | 58.00 | -- | 1.07 | -- | -- | -2.77 | -2.77 | 0.00 | 6.98 | 0.00 | -- | -- | 0.00 | -35.33 | -- | -37.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
Corbus Pharmaceuticals Holdings Inc | 0.00 | -34.97m | 234.98m | 19.00 | -- | 1.79 | -- | -- | -5.82 | -5.82 | 0.00 | 10.92 | 0.00 | -- | -- | 0.00 | -35.74 | -86.84 | -45.03 | -130.46 | -- | -- | -- | -769.76 | -- | -29.78 | 0.0794 | -- | -- | -- | -5.33 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
RA Capital Management LPas of 31 Mar 2024 | 11.61m | 18.68% |
RTW Investments LPas of 31 Mar 2024 | 5.85m | 9.41% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.36m | 8.63% |
TD Securities (USA) LLCas of 30 Jun 2024 | 2.96m | 4.77% |
Suvretta Capital Management LLCas of 31 Mar 2024 | 2.85m | 4.58% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.52m | 4.06% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.49m | 2.40% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 1.35m | 2.18% |
Citadel Advisors LLCas of 31 Mar 2024 | 1.32m | 2.12% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.31m | 2.10% |